

**FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS**

**FOOD AND DRUG ADMINISTRATION**

**OFFICE OF MEDICAL PRODUCTS AND TOBACCO**

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**OFFICE OF GENERIC DRUGS**

Effective Date: 01/24/2014

**1. OFFICE OF GENERIC DRUGS (DKKNU).**

- A. Oversees the development and implementation of standards for the safety and effectiveness of generic drugs.
- B. Reviews and evaluates Abbreviated New Drug Applications (ANDAs) and their amendments or supplements and determines approvability.
- C. Establishes bioequivalency specifications for drug products and develops guidelines for bioequivalency reviews, industry protocols, and studies.
- D. Oversees all aspects of labeling submissions for ANDAs.

**2. CLINICAL SAFETY SURVEILLANCE STAFF (DKKNU1)**

- A. Serves as liaison of OGD with the Office of Surveillance and Epidemiology and other drug surveillance organizations within CDER to obtain information relevant to ensuring the safety of generic drugs on the US market.
- B. Oversees a team of safety personnel to help coordinate inputs to OGD from OSE, OC and external sources, to ensure accuracy of data inputs and assist in gathering needed decision makers within CDER to act on potential emerging safety signals.
- C. Coordinates all tracked safety issues (TSIs).

**3. PROGRAM MANAGEMENT AND ANALYSIS STAFF (DKKNU2)**

- A. Provides leadership and guidance to personnel within the Office of Generic Drugs on all aspects of administrative operations, budget, and facilities management.

- B. Provides service and support for human resource, and personnel operations.
- C. Monitors workflow and proposes improvement in program effectiveness to meet goals and objectives.


**4. COMMUNICATIONS STAFF (DKKNU3)**

- A. Oversees and coordinates all communications, including publications and presentations, that emanate from OGD to ensure quality and consistency with OGD, CDER and agency policies for communication.
- B. Serves as media liaison responsible for all media interactions, and connection to the Office of Communications.
- C. Serves as point of contact (POC) for OGD in heading communications of generic drug safety issues within and outside of CDER

**5. AUTHORITY AND EFFECTIVE DATE.**

The functional statements for this Office were approved by the Secretary of the Department of Health and Human Services and effective on January 24, 2014.

**FOOD AND DRUG ADMINISTRATION  
OFFICE OF MEDICAL PRODUCTS AND TOBACCO  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF GENERIC DRUGS**



Staff Manual Guide 1290.1a  
Organizations and Functions  
Effective Date: January 24, 2014

The following is the Food and Drug Administration, Office of Medical Products and Tobacco, Center for Drug Evaluation and Research, Office of Generic Drugs organization structure depicting all the organizational structures reporting to the Director.

OFFICE OF THE DIRECTOR:

- Clinical Safety Surveillance Staff
- Program Management and Analysis Staff
- Communications Staff
- OFFICE OF RESEARCH AND STANDARDS
- OFFICE OF BIOEQUIVALENCE
- OFFICE OF GENERIC DRUG POLICY
- OFFICE OF REGULATORY OPERATIONS